Skip to main content
PMC home page
Cancers logoLink to Cancers
. 2019 Feb 15;11(2):230. doi: 10.3390/cancers11020230

Does Risk-Adapted Proton Beam Therapy Have a Role as a Complementary or Alternative Therapeutic Option for Hepatocellular Carcinoma?

Tae Hyun Kim 1,2,*,†, Joong-Won Park 1,†, Bo Hyun Kim 1,†, Hyunjung Kim 2, Sung Ho Moon 2, Sang Soo Kim 2, Sang Myung Woo 1, Young-Hwan Koh 1, Woo Jin Lee 1, Dae Yong Kim 2, Chang-Min Kim 1
PMCID: PMC6406298  PMID: 30781391

Abstract

To evaluate the role of risk-adapted proton beam therapy (PBT) in hepatocellular carcinoma (HCC) patients, a total of 243 HCC patients receiving risk-adapted PBT with three dose-fractionation regimens (regimen A [n = 40], B [n = 60], and C [n = 143]) according to the proximity of their gastrointestinal organs (<1 cm, 1–1.9 cm, and ≥2 cm, respectively) were reviewed: The prescribed doses to planning target volume 1 (PTV1) were 50 gray equivalents (GyE) (EQD2 [equivalent dose in 2 Gy fractions], 62.5 GyE10), 60 GyE (EQD2, 80 GyE10), and 66 GyE (EQD2, 91.3 GyE10) in 10 fractions, respectively, and those of PTV2 were 30 GyE (EQD2, 32.5 GyE10) in 10 fractions. In all patients, the five-year local recurrence-free survival (LRFS) and overall survival (OS) rates were 87.5% and 48.1%, respectively, with grade ≥3 toxicity of 0.4%. In regimens A, B, and C, the five-year LRFS and OS rates were 54.6%, 94.7%, and 92.4% (p < 0.001), and 16.7%, 39.2%, and 67.9% (p < 0.001), respectively. The five-year OS rates of the patients with the Modified Union for International Cancer Control (mUICC) stages I, II, III, and IVA and Barcelona Clinic Liver Cancer (BCLC) stages A, B, and C were 69.2%, 65.4%, 43.8%, and 26.6% (p < 0.001), respectively, and 65.1%, 40%, and 32.2% (p < 0.001), respectively. PBT could achieve promising long-term tumor control and have a potential role as a complementary or alternative therapeutic option across all stages of HCC.

Keywords: hepatocellular carcinoma, proton beam therapy, overall survival

1. Introduction

Various treatment options for hepatocellular carcinoma (HCC) are currently available, including liver transplantation, surgical resection, local ablative treatments such as radiofrequency ablation (RFA) and percutaneous ethanol injection (PEI), transarterial chemoembolization (TACE), radioembolization, and molecular targeted agents, such as sorafenib [1,2,3,4]. With technological advances in radiotherapy (RT), new modern RT techniques including three-dimensional conformal RT (CRT), intensity-modulated RT, stereotactic body RT (SBRT), and RT with proton beams and carbon ion beams have recently been applied for HCC patients with or without tumor vascular thrombosis (TVT) and have shown promising outcomes [5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22]. Proton beams, unlike X-rays, have unique physical properties, called Bragg peaks, which allow the delivery of a high dose of radiation to the target volume without exit dose to outside of the target volume. Our previous study showed that proton beam therapy (PBT) could spare the normal liver more effectively than RT with X-rays [23]. In addition, a recent meta-analysis [24] showed that charged particle therapy has higher rates of survival than CRT, similar to SBRT, and PBT tends to result in a lower incidence of adverse events than CRT and SBRT.

HCC patients have poor functional reserves resulting from underlying liver cirrhosis (LC), and primary tumors and/or TVT are often located near radiosensitive tissues, such as the gastrointestinal (GI) organs; thus, when RT is performed in HCC patients with or without TVT, it is important to spare both the remaining normal liver and GI organs. The PBT using simultaneous integrated boost (SIB) technique, which simultaneously delivers different doses to different targets, can potentially reduce irradiated doses to surrounding normal tissues and overall time of treatment and improve the therapeutic ratio compared to conventional fractionated PBT. Based on this rationale, risk-adapted PBT using the SIB technique has been used for HCC patients with or without TVT at our institution from June 2012. The purpose of this study was to evaluate the long-term efficacy and safety of risk-adapted PBT in these patients.

2. Results

A total of 314 patients treated with PBT for HCC from June 2012 to April 2017 were registered. Of these, 71 patients did not meet the eligibility criteria for the following reasons: 48 were treated with PBT using different dose-fractionation regimens, 11 had extrahepatic disease, four had uncontrolled intrahepatic disease outside of the PBT site, four had Child-Pugh class B8-9 or C, and four were transferred to other hospitals immediately after PBT. The remaining 243 patients who met all of the inclusion criteria were analyzed in this study; this included 122 patients who participated in the phase II trial for risk-adapted PBT using three dose-fractionation regimens (NCC20120622), and 121 patients who did not participate (Table 1). Because of the proximity of the GI structures, the frequencies of large tumor sizes, TVT, advanced tumor stage, concurrent sorafenib, and post-treatment to the PBT site were significantly lower in the order of regimen A, B, and C (p < 0.05) (Table 1).

Table 1.

Patient characteristics in all patients and subgroups according to dose-fractionation (Dose-Fx) regimens.

Characteristics Total Dose-Fx Regimen A Dose-Fx Regimen B Dose-Fx Regimen C p Value
n (%) n (%) n (%) n (%)
Gender Male 211 (86.8) 34 (85.0) 53 (88.3) 124 (86.7) 0.888 *
Female 32 (13.2) 6 (15.0) 7 (11.7) 19 (13.3)
Age, years Median (range) 61 (24–92) 59 (24–81) 62.5 (39–80) 62 (34–92) 0.133 †
<60 100 (41.2) 22 (55.0) 24 (40.0) 54 (37.8) 0.144 *
≥60 143 (58.8) 18 (45.0) 36 (60.0) 89 (62.2)
ECOG PS 0 237 (97.5) 38 (95.0) 59 (98.3) 140 (97.9) 0.520 *
1 6 (2.5) 2 (5.0) 1 (1.7) 3 (2.1)
Etiology of LC HBV 188 (77.4) 33 (82.5) 45 (75.0) 110 (76.9) 0.799 *
HCV 20 (8.2) 3 (7.5) 6 (10.0) 11 (7.7)
Alcoholic 17 (7.0) 1 (2.5) 6 (10.0) 10 (7.0)
Unknown 18 (7.4) 3 (7.5) 3 (5.0) 12 (8.4)
Child-Pugh A 228 (93.8) 36 (90.0) 54 (90.0) 138 (96.5) 0.117 *
Classification B7 15 (6.2) 4 (10.0) 6 (10.0) 5 (3.5)
AFP, ng/mL Median (range) 10.2 (1.2–38,396.4) 25.3 (1.9–31,466.3) 10.9 (2.2–38,396.4) 9.3 (1.2–16,788.3) 0.062 †
<10 120 (49.4) 14 (35.0) 30 (50.0) 76 (53.1) 0.127 *
≥10 123 (50.6) 26 (65.0) 30 (50.0) 67 (46.9)
Tumor size, cm Median (range) 2.2 (1.0–17) 6.0 (1.3–17) 3.6 (1.0–12) 1.5 (1.0–12.7) <0.001 †
≤2 115 (47.3) 1 (2.5) 16 (26.7) 98 (68.5) <0.001 *
>2 128 (52.7) 39 (97.5) 44 (73.3) 45 (31.5)
TVT No 184(75.7) 11 (27.5) 40 (66.7) 133 (93.0) <0.001 *
Branch 29 (11.9) 7 (17.5) 15 (25.0) 7 (4.9)
Main 30 (12.3) 22 (55.0) 5 (8.3) 3 (2.1)
mUICC stage I 13 (5.3) 1 (2.5) 2 (3.3) 10 (7.0) <0.001 *
II 74 (30.5) 1 (2.5) 13 (21.7) 60 (42.0)
III 106 (43.6) 12 (30.0) 31 (51.7) 63 (44.1)
IVA 50 (20.6) 26 (65.0) 14 (23.3) 10 (7.0)
BCLC stage A 97 (39.9) 0 (0) 17 (28.3) 80 (55.9) <0.001 *
B 86 (35.4) 11 (27.5) 22 (36.7) 53 (37.1)
C 60 (24.7) 29 (72.5) 21 (35.0) 10 (7.0)
Diagnosis at PBT Primary 10 (4.1) 5 (12.5) 2 (3.3) 3 (2.1) 0.021
Recurrence 233 (95.9) 35 (87.5) 58 (96.7) 140 (95.9)
Pre-Tx to PBT site No 52 (21.4) 7 (17.5) 4 (6.7) 41 (28.7) 0.002 *
Yes 191 (78.6) 33 (82.5) 56 (93.3) 102 (71.3)
LRT 186 (97.4) 27 (81.8) 54 (96.4) 102 (97.4)
LRT + sorafenib 5 (2.6) 3 (9.1) 2 (3.6) 0 (0)
Sorafenib ± chemo 3 (1.6) 3 (9.1) 0 (0) 0 (0)
Pre-Tx to other site No 70 (28.8) 22 (55.0) 23 (38.3) 25 (17.5) <0.001 *
Yes 173 (43.9) 18 (45.0) 37 (61.7) 118 (82.5)
LRT 171 (98.3) 18 (100) 36 (97.3) 117 (98.3)
LRT + sorafenib 3 (1.7) 0 (0) 1 (2.7) 2 (1.7)
Concurrent Tx No 236 (97.1) 34 (85.0) 59 (98.3) 143 (100) <0.001 *
Sorafenib 7 (2.9) 6 (15.0) 1 (1.7) 0 (0)
Post-Tx to PBT site No 195 (80.2) 12 (30.0) 48 (80.0) 135 (94.4) <0.001 *
Yes 48 (19.8) 28 (70.0) 12 (20.0) 8 (5.6)
LRT 16 (33.3) 7 (25.0) 7 (58.3) 2 (25.0)
LRT ± sorafenib ± chemo 7 (14.6) 6 (21.4) 0 (0) 1 (12.5)
Sorafenib ± chemo 25 (52.1) 15 (53.6) 5 (41.7) 5 (62.5)
Post-Tx to other site No 66 (27.2) 8 (20.0) 18 (30.0) 40 (28.0) 0.515 *
Yes 177 (72.8) 32 (80.0) 42 (70.0) 103 (72.0)
LRT 91 (51.7) 4 (12.5) 19 (45.2) 68 (66.0)
LRT ± sorafenib ± chemo 57 (32.4) 17 (51.1) 15 (35.7) 26 (25.2)
Sorafenib ± chemo 28 (15.9) 11 (34.4) 8 (19.0) 9 (8.7)
Open in a new tab

Abbreviations: LC, liver cirrhosis; HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, α-fetoprotein; ECOG, Eastern Cooperative Oncology Group; PS, performance status; TVT, tumor vascular thrombosis; mUICC stage, modified International Union Against Cancer stage; BCLC stage, Barcelona Clinic Liver Cancer stage; Tx, treatment; PBT, proton beam therapy; LRT, locoregional treatment including surgical resection, radiofrequency ablation, percutaneous ethanol injection, transarterial chemoembolization, and radiotherapy; chemo, systemic chemotherapy. * Fisher’s exact test, two-tail. † One-way analysis of variance.

Primary tumor and TVT responses for all patients were complete response (CR) in 199 (81.9%) and 30 (50.8%), respectively; partial response (PR) in 30 (12.3%) and 18 (30.5%), respectively; stable disease in 13 (5.3%) and 10 (16.9%), respectively; and progressive disease in 1 (0.4%) and 1 (1.7%), respectively (Table 2) (Figure 1A–I). Median times to CR of the primary tumor and TVT after PBT were 4.5 months (range 1–21.7 months) and 5.1 months (range 1.1–16.4 months), respectively. The CR and objective response (CR + PR) rates of primary tumor and TVT were significantly lower in regimen A than in regimens B and C (p < 0.05 each) (Table 2). Not surprisingly, the patients who had CR less frequently received post-treatment to the PBT site than those who did not have CR (25 of 199 [12.7%] vs. 16 of 37 [43.2%], p < 0.001) (Table 2).

Table 2.

Primary tumor and tumor vascular thrombosis (TVT) response according to dose-fractionation regimens and pre- and post-treatment (Tx).

Response Dose-Fractionation Regimen, n (%) p Value * Pre-Tx to PBT Site, n (%) p Value * Post-Tx to PBT Site, n (%) p Value *
Regimen A Regimen B Regimen C No Yes No Yes
Primary tumor CR 16 (40.0) 51 (85.0) 132 (92.3) <0.001 47 (90.4) 152 (79.6) 0.405 174 (89.2) 25 (53.1) <0.001
(n = 243) PR 18 (45.0) 6 (10.0) 6 (4.2) 4 (7.7) 26 (13.6) 16 (8.2) 14 (29.2)
SD 6 (15.02) 2 (3.3) 5 (3.5) 1 (1.9) 12 (6.3) 5 (2.6) 1 (2.1)
PD 0 (0.0) 1 (1.7) 0 (0.0) 0 (0.0) 1 (0.5) 0 (0.0) 1 (2.1)
TVT CR 9 (31.0) 15 (75.0) 6 (60.0) 0.021 3 (42.9) 27 (51.9) 0.877 15 (60.0) 15 (44.1) 0.610
(n = 59) PR 12 (41.4) 3 (15.0) 3 (30.0) 3 (42.9) 15 (28.9) 7 (28.0) 11 (32.4)
SD 8 (27.6) 1 (5.0) 1 (10.0) 1 (14.2) 9 (17.3) 3 (12.0) 7 (20.6)
PD 0 (0.0) 1 (5.0) 0 (0.0) 0 (0.0) 1 (1.9) 0 (0.0) 1 (2.9)
Open in a new tab

Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; the others are the same as Table 1. * Fisher’s exact test.

Figure 1.

Figure 1

Open in a new tab

The cases showing objective tumor response after risk-adapted proton beam therapy (PBT) with three dose-fractionation regimens (regimen A, B, and C) according to the proximity of the gastrointestinal organs (<1 cm [A–C], 1–1.9 cm [D–F], and ≥2 cm [G–I], respectively). A, D, and G: Pre-treatment computed tomography (CT) scans showing the primary tumor and/or tumor vascular thrombosis (TVT) (arrow). B, E, and H: The patient received risk-adapted PBT (50 GyE, 60 GyE, and 66 GyE in 10 fractions to PTV1, respectively, and 30 GyE in 10 fractions to PTV2). C, F, and I: One-year follow-up CT scans after risk-adapted PBT showing notable reductions of the primary tumor and/or TVT (arrow). Abbreviations: PTV, planning target volume.

At the time of analysis, 145 patients were alive, and 98 died by disease progression (n = 86), progressive liver failure induced by underlying LC (n = 8), pneumonia (n = 1), intracranial hemorrhage (n = 1), biliary complications by post-treatment (n = 1), and cardiomyopathy due to chemotherapy (n = 1) unrelated to PBT. The median follow-up time of all and living patients were 31.5 months (range 2.1–68.2 months) and 39.3 months (range 13.2–68.2 months), respectively. Disease recurrence occurred in 190 (78.2%) patients: 24 (12.6%) had local recurrence, 175 (92.1%) had intrahepatic recurrence, and 70 (36.8%) had distant metastases (Figure 2). In all patients, the median time of OS was 56.6 months (95% confidence interval [CI], 45.8–67.2 months) and the three- and five-year local recurrence-free survival (LRFS), recurrence-free survival (RFS), and overall survival (OS) rates were 88.6% (95% CI, 84.1–93.1%) and 87.5% (95% CI, 82.6–92.4%), and 18.8% (95% CI, 13.5–24.1%) and 12.4% (95% CI, 6.3–18.5%), and 61.8% (95% CI, 55.1–68.5%), and 48.1% (95% CI, 39.1–57.1%), respectively. In the patients treated with regimens A, B, and C, the five-year LRFS, RFS, and OS rates were 54.6% (95% CI, 32.6–76.7%), 94.7% (95% CI, 88.8–100%), and 92.4% (95% CI, 87.5–97.3%) (p < 0.001), 10% (95% CI, 0.2–19.8%), 12.9% (95% CI, 0.4–25.4%), and not reached (NR) (95% CI, -) (p = 0.038), and 16.7% (95% CI, 3.6–29.8%), 39.2% (95% CI, 24.9–53.5%), and 67.9% (95% CI, 57.5–78.3%), respectively (p < 0.001) (Figure 3A). In those who had CR or not, the five-year LRFS, RFS, and OS rates were 94% (95% CI, 89.7–98.35) and NR (p < 0.001), 14.9% (95% CI, 7.8–22%) and NR (95% CI, -) (p < 0.001), and 60.9% (95% CI, 51.5–70.3%) and 0% (p < 0.001), respectively (Figure 3B). In those with modified International Union Against Cancer (mUICC) stages I, II, III, and IVA, the five-year LRFS, RFS, and OS rates were 100% (95% CI, -), 94% (95% CI, 87.3–100%), 88.9% (95% CI, 82.2–95.6%), and 65.5% (95% CI, 58.8–88.6%) (p < 0.001), 23.4% (95% CI, 0–49.5%), 27.3% (95% CI, 15.5–39.1%), 0.4% (95% CI, 0–6.9%), and 11.8% (95% CI, 2.4–21.2%)(p < 0.001), and 69.2% (95% CI, 28.6–100%), 65.4% (95% CI, 45.8–85%), 43.8% (95% CI, 31.3–56.3%), and 26.6% (95% CI, 12.7–40.5%) (p < 0.001), respectively (Figure 3C). In those with Barcelona Clinic Liver Cancer (BCLC) stages A, B, and C, the five-year LRFS, RFS, and OS rates were 93.6% (95% CI, 87.9–99.3%), 89.7% (82.3–97.1%), and 72.3% (95% CI, 57–87.6%) (p = 0.001), 17.6% (95% CI, 7.8–27.4%), 0% (95% CI, -), and 16.4% (95% CI, 6.6–26.2%) (p = 0.022), and 65.1% (95% CI, 50.2–80%), 40% (95% CI, 26.1–53.9%), and 32.2% (95% CI, 16.0–48.6%) (p < 0.001), respectively (Figure 3D).

Figure 2.

Figure 2

Open in a new tab

Patterns of failure. Abbreviations: LR, local recurrence; IHR, intrahepatic recurrence; DM, distant metastasis.

Figure 3.

Figure 3

Open in a new tab

Overall survival (OS) curves according to dose-fractionation regimens (A), primary tumor response (B), mUICC stage (C), and BCLC stage (D). Abbreviations: mUICC stage, modified International Union against Cancer stage; BCLC stage, Barcelona Clinic Liver Cancer stage; yr, year; CI, confidence interval; CR, complete response. * Log-rank test.

Except for gender, age, performance status, etiology of LC, diagnosis at PBT, and pre- and post-treatment to other sites, all clinical factors were significantly associated with OS in univariate analysis (Table 3). In multivariate analysis, the Child–Pugh classification, alpha-fetoprotein (AFP) level, mUICC stage, dose-fractionation regimens, and primary tumor response were significantly associated with OS (p < 0.05 each) (Table 3).

Table 3.

Univariate and multivariate analysis of factors associated with overall survival (OS).

Characteristics Univariate † Multivariate ‡
1-yr OS, % (95% CI) 3-yr OS, % (95% CI) 5-yr OS, % (95% CI) Median OS, Months (95% CI) p Value Hazard Ratio (95% CI) p Value
Gender Male 87.7 (83.2–92.2) 62.2 (55.1–69.3) 48.3 (38.5–58.1) 56.5 (45.5–67.2) 0.964 - NS
Female 96.9 (90.8–100) 60.2 (42.6–77.8) 49.3 (29.3–69.3) 46.6 (-) -
Age, years <60 88.0 (81.7–94.3) 63.3 (53.3–73.3) 45.0 (29.1–60.9) 56.5 (35.1–77.9) 0.945 - NS
≥60 89.5 (84.4–94.6) 60.8 (52.0–69.6) 49.5 (38.3–60.7) 55.0 (44.5–65.5) -
ECOG PS 0 88.6 (84.5–92.7) 62.8 (56.1–69.5) 48.6 (39.4–57.8) 56.5 (44.9–68.0) 0.175 - NS
1 100 (-) 25.0 (0–65.0) - (-) 21.2 (4.1–38.4) -
Etiology of LC HBV 88.8 (84.3–93.3) 62.4 (55.0–69.8) 49.4 (39.2–59.6) 56.5 (-) 0.784 - NS
Others 89.1 (80.9–97.3) 60.0 (45.5–74.5) 44.9 (26.1–63.7) 55.0 (32.0–78.0) -
Child-Pugh Classification A 90.4 (86.5–94.3) 65.3 (58.6–72.0) 50.5 (41.1–59.9) 60.3 (-) <0.001 1.000 0.016
B7 66.7 (42.8–90.6) 0.91 (0–26.0) 0.91 (0–26.0) 17.1 (1.6–32.6) 2.221 (1.162–4.246)
AFP, ng/mL <10 92.5 (87.8–97.2) 74.3 (65.7–82.9) 56.3 (41.6–71.0) NR <0.001 1.000 0.008
≥10 85.4 (79.1–91.7) 49.9 (40.5–59.3) 39.6 (28.6–50.6) 34.3 (24.4–44.2) 1.773 (1.158–2.713)
Tumor size, cm ≤2 94.8 (90.7–98.9) 79.5 (71.5–87.5) 64.4 (49.3–7.5) NR <0.001 - NS
>2 83.6 (77.1–90.1) 46.5 (37.1–55.9) 34.0 (23.6–44.4) 33.9 (28.4–39.5) -
TVT No 93.5 (90.0–97.0) 67.8 (60.4–75.3) 54.1 (43.9–64.3) 60.3 (-) <0.001 – NS
Branch 79.3 (60.4–91.4) 49.0 (29.8–68.2) 49.0 (29.8–68.2) 34.3 (-)
Main 73.3 (57.4–89.2) 38.8 (21.0–56.6) 18.9 (0–38.1) 19.4 (6.1–32.8) -
mUICC stage I 100 (-) 92.3 (77.8–100) 69.2 (28.6–100) NR <0.001 1.000
II 94.6 (89.5–99.7) 83.9 (74.5–93.3) 65.4 (45.8–85) NR 3.186 (0.699–14.525) 0.134
III 93.4 (88.7–98.1) 57.0 (46.8–67.2) 43.8 (31.3–56.3) 46.6 (34.9–58.4) 6.563 (1.557–27.669) 0.010
IVA 68.0 (55.1–80.9) 33.4 (19.7–47.1) 26.6 (12.7–40.5) 19.4 (10.0–28.8) 7.119 (1.673–30.288) 0.008
BCLC stage A 96.9 (93.4–100) 80.1 (71.5–88.7) 65.1 (50.2–80.0) NR <0.001 - NS
B 89.5 (83.0–96.0) 53.9 (42.3–65.5) 40.0 (26.1–53.9) 37.1 (24.2–50.1) -
C 75.0 (64.0–86.0) 44.6 (31.5–57.7) 32.2 (16.0–48.6) 33.9 (16.2–51.7) -
Diagnosis at PBT Primary 90.0 (71.4–100) 56.0 (22.5–89.5) 42.0 (7.5–76.5) 38.4 (8.5–68.2) 0.578 - NS
Recurrence 88.8 (83.8–92.1) 62.0 (55.3–68.7) 48.2 (38.8–57.6) 56.5 (45.3–67.7) -
Pre-Tx to PBT site No 98.1 (94.4–100) 82.3 (71.1–93.5) 78.4 (65.3–91.5) NR <0.001 - NS
Yes 86.4 (81.5–91.3) 56.8 (49.4–64.2) 41.7 (32.1–51.3) 46.9 (33.7–60.1) -
Pre-Tx to other site No 87.1 (79.3–94.9) 54.0 (41.3–66.7) 41.4 (26.3–56.5) 38.4 (19.7–57.1) 0.130 - NS
Yes 89.6 (85.1–94.1) 64.9 (57.3–72.5) 51.2 (39.8–62.5) NR -
Concurrent Tx No 89.8 (85.9–93.7) 62.8 (56.1–69.5) 49.4 (38.0–60.8) 56.5 (-) 0.001 - NS
Sorafenib 57.1 (20.4–93.8) 28.6 (0–62.1) 0 (-) 19.4 (0–40.3) -
Post-Tx to PBT site No 93.8 (90.5–97.1) 67.5 (60.2–74.8) 53.8 (42.6–65.0) 60.3 (-) <0.001 - NS
Yes 68.7 (55.6–81.8) 40.2 (25.9–54.5) 26.2 (12.5–39.9) 25.4 (7.1–43.7) -
Post-Tx to other sites No 81.8 (72.6–91.0) 68.8 (56.8–80.8) 61.9 (45.2–78.6) NR 0.294 - NS
Yes 91.5 (87.3–95.6) 59.8 (52.2–67.4) 44.3 (34.1–54.5) 48.7 (36.3–61.1) -
Dose-fractionation Regimen A 75.0 (61.7–88.3) 33.3 (18.4–48.2) 16.7 (3.6–29.8) 23.4 (15.3–31.5) <0.001 2.045 (1.244–3.362) 0.005
Regimen B 86.7 (78.1–95.3) 51.2 (38.1–64.3) 39.2 (24.9–53.5) 40.8 (19.7–61.9) 1.298 (0.740–2.277) 0.363
Regimen C 93.7 (89.8–97.6) 76.0 (68.4–83.6) 67.9 (57.5–78.3) NR 1.000
Primary tumor response CR 97.0 (94.6–99.4) 73.3 (66.6–80.0) 60.9 (51.5–70.3) NR <0.001 1.000 <0.001
Non-CR 52.3 (37.6–67.0) 10.6 (1.0–20.2) 0 (-) 13.7 (10.8–16.6) 7.012 (4.324–11.370)
Open in a new tab

Abbreviations: yr, year; NR, not reached; NS, not significant; CI, confidence interval; the others are the same as in Table 1 and Table 2. † Log-rank test. ‡ Cox proportional hazards model.

Acute adverse effects within three months after PBT were easily manageable and did not cause discontinuation of the treatment course. Of the 243 patients, 10 (4.1%) and one (0.4%) experienced grade 1 and 2 elevated alanine aminotransferase without disease progression, respectively, and 213 (87.7%) had no change in their Child–Pugh scores, 19 (7.8%) had a 1-point decrease, 10 (4.1%) had a 1-point increase, and one (0.4%) had a 2-point increase due to biliary obstruction by tumor progression. Thirty-two (13.2%) and two (0.8%) patients experienced grades 1 and 2 leukopenia, respectively, and 19 (7.8%) and one (0.4%) experienced grades 1 and 2 thrombocytopenia, respectively. Of 40 patients treated with regimen A, late GI toxicities, defined as gastric or duodenal ulcers within the PBT field, were observed in five (12.5%) patients, including one (2.5%), three (7.5%), and one (2.5%) with grades 1, 2, and 3, respectively. None of the patients treated with regimens B and C experienced GI bleeding and ulcer, and treatment-related hepatic failure and death were not observed.

3. Discussion

Surgical resection, liver transplantation and local ablative treatments, such as RFA and PEI, have been considered as curative treatments [1,3,4]. In patients with BCLC stage A, these curative treatments may offer five-year OS rates of 50–70% [1,25,26,27]. However, these curative treatments have been performed in selected patients because of the multi-centricity of HCC development, patient comorbidities, the lack of transplant donors, bleeding tendency, unsuitable location, non-echogenicity, or large tumor sizes. Fukuda et al. [7] reported five-year LRFS and OS rates of 94% and 69%, respectively, in previously untreated BCLC 0/A HCC patients who received PBT with 66–77 GyE in 10–35 fractions. Similarly, the present study also showed that the risk-adapted PBT using 50–66 GyE in 10 fractions for BCLC A HCC patients who were unsuitable or ineffective with other loco-regional treatments (LRTs) resulted in five-year LRFS and OS rates of 93.6% and 65.1%, respectively, which was comparable to those in patients treated with curative treatments including surgical resection and local ablative treatments in data from our institutional cohort [27] and previous studies [1,25,26]. These results suggest that PBT can be considered an effective alternative option for BCLC A patients.

TACE is considered a first-line treatment for BCLC B HCC patients who have unresectable tumors and are unsuitable for local ablative treatments [1,3,4]. The expected median survival time is >30 months [1]. In our institutional cohort data [27], BCLC B patients had a median OS of 32.5 months and a five-year OS rate of 34.3%. The mUICC I/II and III patients who were treated with TACE had five-year OS rates of 55.2% and 25.2%, respectively. In the present study, risk-adapted PBT resulted in median OS of 37.1 months and five-year OS rates of 40% in BCLC B patients, and five-year OS rates of 69.2%, 65.4%, and 43.8% in mUICC I, II, and III patients. In BCLC C patients, although sorafenib has been considered a first-line treatment with an expected median OS of ≥10 months [1,25,26], TACE remains the most frequently used initial treatment [27,28,29]. In our institutional cohort data [27], BCLC C patients had a median OS of 10.3 months and five-year OS rates of 17.1%, and the mUICC IVA patients treated with TACE had a median OS of 7.8 months and five-year OS rates of 5.9%. The present study showed a median OS of 33.9 months and a five-year OS of 33.9% in BCLC C patients and a median OS of 19.4 months and a five-year OS of 26.6% in mUICC IVA patients. Although there were differences in patient characteristics and selection bias among the studies, these PBT results for BCLC B and C patients might be comparable or superior to those of any TACE and sorafenib.

HCC lesion(s) and/or TVT are frequently adjacent to the GI organs. When considering RT for HCC patients, it is important to safely deliver a high dose of radiation to the tumor and/or TVT within tolerances of these organs. For these reasons, we applied risk-adapted PBT using three dose-fractionation regimens, depending on the proximity of the GI organs, and showed that risk-adapted PBT could be performed in all patients with grade ≥3 GI toxicity of 0.4%. Only one of 40 (2.5%) patients treated with regimen A (EQD2, 62.5 GyE10) for HCC <1 cm from the GI organs experienced grade 3 GI toxicity. No patients treated with regimens B (EQD2, 80 GyE10) and C (EQD2, 91.3 GyE10) for HCC 1–1.9 cm and ≥2 cm from the GI organs, respectively, experienced grade ≥3 GI toxicity. The five-year LRFS (54.6%, 94.7%, and 92.4%), RFS (10%, 12.9%, and NR), and OS rates (16.7%, 39.2%, and 67.9%) were significantly higher in the patients treated with regimens B and C (EQD2 ≥ 80 GyE10) than in those treated with regimen C (EQD2 < 80 GyE10) (Table 3). In other studies [20,22], PBT using relative long fractionation regimens (53.7–88 GyE10/24–38 fractions or 80.1–91.5 GyE10/22–35 fractions, respectively) showed a two-year LPFS rate of 94% and three-year LPFS of 88.1%, respectively, and grade ≥3 GI toxicity of 2.5% and 2.1%, respectively. In the present study, there were significant differences in patient characteristics including tumor size, stage, extent of TVT, etc., among three dose-fractionation regimens (Table 1). Thus, large HCC was more likely to close to GI organs and treat with regimen A rather than regimen B and C, and subsequently poor local tumor control in regimen A than regimen B and C. In addition, the incidence of grade ≥3 GI toxicity in the patients treated with regimen A was as low as 2.5%. These findings suggest that it might be possible to carefully escalate the radiation doses for patients with HCC <1 cm from the GI organs to improve tumor control and survival.

This study had inherent limitations from single institutional retrospective data with a heterogeneous population including recurrent, ineffective, and/or unsuitable tumor with other LRTs. The effects of pre- and post-treatments on intrahepatic and/or metastatic disease and possible selection bias were not thoroughly assessed. Nevertheless, to date, the present study was a relatively large-size study treating patients with risk-adapted PBT using consistent techniques, and the outcomes of risk-adapted PBT were compared to those of current established therapeutic options, such as surgical resection, local ablative treatments, TACE, and sorafenib, with relatively large-scale institutional cohort data (n = 1972) [27]. In addition, tumor response and dose-fractionation regimens were significantly associated with LRFS and OS. These findings suggest that dose-escalation using risk-adapted PBT may improve LRFS and subsequently improve OS.

4. Materials and Methods

4.1. Patients

Patients who were treated with PBT for primary or recurrent HCC from June 2012 to April 2017 were registered and the database was reviewed. Inclusion criteria for the present study were: (i) HCC was diagnosed by pathologic confirmation or radiologic findings plus serum alpha-fetoprotein (AFP) concentrations ≥200 ng/mL, according to the guidelines of the Korean Liver Cancer Study Group and the National Cancer Center (NCC) [3]; (ii) HCC lesions were unsuitable, ineffective, or refused for any other loco-regional treatments (LRTs), including surgical resection, RFA, TACE, PEI, etc.; (iii) patients were treated with risk-adapted PBT using three dose-fractionation regimens depending on the proximity of the GI organs; (iv) there was no uncontrolled intrahepatic disease outside of the targeted lesion; (v) liver function of Child–Pugh class A or B7 was present; (vi) no extrahepatic metastasis; and (vii) there was no previous history of RT to the liver. The Modified Union for International Cancer Control (mUICC) [30] and the Barcelona Clinic Liver Cancer (BCLC) [25] staging classification were used for tumor and clinical staging, respectively. This study was approved by the institutional review board of NCC (NCC20180100), and informed consent was not required because of the retrospective nature of this research.

4.2. Treatment

The details of the risk-adapted PBT plan have been described in previous reports [11,13,14,15,17]. In brief, contrast-enhanced four-dimensional computed tomography (CT) scanning was performed under monitoring with a real-time position management (RPM) system (Varian Medical Systems, Palo Alto, CA, USA). All obtained CT images were resorted into 10 equally spaced respiratory phases and average intensity projection (AIP)-CT images were reconstructed with the exhalation (gated) phases (30% of total respiratory cycle) CT images. All tumors detected in the AIP-CT images were defined as the gross tumor volume (GTV) without clinical target volume margins from GTVs [5,11,13,14,15,17,31]. The sum of the GTVs, defined as the internal target volume (ITV), and the contours of the organs at risk (OARs) in each CT image during the gated phases were delineated. The planning target volumes (PTV) 1 and 2 included the ITV with a margin of 5–7 mm in all directions with and without excluding the 10-mm expanded volume of the GI organs, respectively (Figure 1D–F). Typically, PBT plans (Version 8.1; Varian Medical System, Palo Alto, CA, USA) were performed using one beam of 230 MeV proton beams of Proteus 235 (Ion Beam Applications, S.A., Louvain-la-Neuve, Belgium) to cover the PTV1 and two beams to cover the PTV2. The proximal, distal, border smoothing, smearing, and aperture margins of the proton beams with the double-scattering mode to PTV were set to 5–7 mm each. The radiation doses for the target volumes and the OARs were described in gray equivalents (GyE = proton physical dose [in gray] × relative biologic effectiveness [1.1]) and the equivalent dose in 2 Gy fractions (EQD2, GyE10, or GyE3) was calculated using a linear quadratic model with α/β of 10 and 3 for the acute and late effects, respectively (EQD2 = total dose × [(fraction dose + α/β)/(2 + α/β)]) [32]. The plan was designed so that at least 95% of the PTV would receive 100% of each prescribed dose. Three dose-fractionation regimens were used according to the proximity of the GI organs as described in our previous report [11]: (1) For regimen A, the prescribed doses to PTV1 and PTV2 were 50 GyE (EQD2, 62.5 GyE10) and 30 GyE (EQD2, 32.5 GyE10) in 10 fractions, 5 fractions a week, respectively, for the patients with GTV <1 cm from the GI organs; (2) for regimen B, the prescribed doses to PTV1 and PTV2 were 60 GyE (EQD2, 80 GyE10) and 30 GyE in 10 fractions, respectively, for the patients with GTV within 1–1.9 cm from the GI organs; and (3) for regimen C, the prescribed dose to PTV1, identical to PTV2, was 66 GyE (EQD2, 91.3 GyE10) in 10 fractions for the patients with GTV ≥2 cm from the GI organs. The dose-volume constraints for the OARS were described previously [11,13,14,15,17,33]. The relative volumes of the total and remaining normal liver receiving ≥27 GyE were below 60% and 50%, respectively, and the absolute volumes of the stomach and small and large bowel receiving ≥37 GyE and ≥35 GyE, respectively, were less than 2 cm3. At each treatment, to reduce intra- and inter-fractional uncertainties, all patients were asked to fast for at least 4 hours prior to treatment and irradiation was delivered during the gated phase after verifying each patient’s position and isocenter.

4.3. Evaluation and Statistical Considerations

During PBT, the patients were evaluated weekly and, after completion of PBT, at 1 month, every 3 months for the first 2 years, and every 6 months thereafter. Physical examination, complete blood counts, liver-function tests, chest X-ray, and liver dynamic contrast-enhanced CT or magnetic resonance imaging were performed at each follow-up. TVT in the main, right, and left lobar branches of the portal vein, hepatic vein, and inferior vena cava were classified as “Main” and the other segmental and sectional branches of the portal vein and hepatic vein were classified as “Branch.” The responses of the primary tumor and TVT were defined as the maximal tumor response observed during the follow-up period comparing CT scans before and after PBT, according to the modified Response Evaluation Criteria in Solid Tumors criteria (mRECIST) [34]. Adverse effects related to PBT were graded according to Common Terminology Criteria for Adverse Events (CTCAE; version 4.0, https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/)

Recurrence was proven by pathologic and/or radiologic findings showing an increase in size over time. Local, intrahepatic, and distant recurrence was defined as a regrowth or new tumor within the treated volume, a regrowth or new intrahepatic tumor outside of the treated volume, and the development of an extrahepatic tumor, respectively. Overall survival (OS), recurrence-free survival (RFS), and local recurrence-free survival (LRFS) were estimated from the date of the start of PBT to the date of death or last follow-up, any recurrence, and local recurrence, respectively. The distributions of clinical characteristics among dose-fractionation regimens ware compared using Fisher’s exact test or one-way analysis of variance, and the differences of primary tumor and TVT responses according to dose-fractionation regimens were assessed using Fisher’s exact test. The probability of survival was calculated using the Kaplan–Meier method and, in univariate analysis, the log-rank test was used to evaluate the effects of the factors on survival. Multivariate analysis was performed using Cox’s proportional hazard model with a stepwise forward selection procedure. Differences with p values of <0.05 were considered statistically significant, and variables with p < 0.1 in univariate analysis were entered into multivariate analysis. All statistical analyses were performed using STATA software (version 14.0; StataCorp., College Station, TX, USA).

5. Conclusions

This study shows that risk-adapted PBT using three dose-fractionation regimens could achieve long-term tumor control with minimal toxicity, suggesting that PBT might play a potential role as a complementary or alternative therapeutic option across all stages of HCC that are unsuitable or ineffective with other LRTs.

Author Contributions

Conceptualization, T.H.K., J.-W.P., B.H.K., and D.Y.K.; data curation, T.H.K., H.K., and S.H.M.; formal analysis, T.H.K. and S.S.K.; Writing—Original draft preparation, T.H.K.; Writing—Review and editing, T.H.K., J.-W.P., B.H.K., H.K., S.H.M., S.S.K., S.M.W., Y.-H.K., W.J.L., D.Y.K., and C.-M.K.; supervision, T.H.K., J.-W.P., and B.H.K.

Funding

This study was supported by the National Cancer Center Grant (NCC 1810271 and 1710030). The funding source had no role in study design, data collection, analysis or interpretation of data.

Conflicts of Interest

The authors declare no conflict of interest.

References

  • 1.European Association for the Study of the Liver EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2018;69:182–236. doi: 10.1016/j.jhep.2018.03.019. [DOI] [PubMed] [Google Scholar]
  • 2.Heimbach J.K., Kulik L.M., Finn R.S., Sirlin C.B., Abecassis M.M., Roberts L.R., Zhu A.X., Murad M.H., Marrero J.A. Aasld guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358–380. doi: 10.1002/hep.29086. [DOI] [PubMed] [Google Scholar]
  • 3.Korean Liver Cancer Study Group. National Cancer Center Practice guidelines for management of hepatocellular carcinoma 2009. Korean J. Hepatol. 2009;15:391–423. doi: 10.3350/kjhep.2009.15.3.391. [DOI] [PubMed] [Google Scholar]
  • 4.Korean Liver Cancer Study Group. National Cancer Center 2014 KLCSG-NCC Korea practice guideline for the management of hepatocellular carcinoma. Gut Liver. 2015;9:267–317. doi: 10.5009/gnl14460. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Bujold A., Massey C.A., Kim J.J., Brierley J., Cho C., Wong R.K., Dinniwell R.E., Kassam Z., Ringash J., Cummings B., et al. Sequential phase i and ii trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J. Clin. Oncol. 2013;31:1631–1639. doi: 10.1200/JCO.2012.44.1659. [DOI] [PubMed] [Google Scholar]
  • 6.Bush D.A., Kayali Z., Grove R., Slater J.D. The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: A phase 2 prospective trial. Cancer. 2011;117:3053–3059. doi: 10.1002/cncr.25809. [DOI] [PubMed] [Google Scholar]
  • 7.Fukuda K., Okumura T., Abei M., Fukumitsu N., Ishige K., Mizumoto M., Hasegawa N., Numajiri H., Ohnishi K., Ishikawa H., et al. Long-term outcomes of proton beam therapy in patients with previously untreated hepatocellular carcinoma. Cancer Sci. 2017;108:497–503. doi: 10.1111/cas.13145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Fukumitsu N., Sugahara S., Nakayama H., Fukuda K., Mizumoto M., Abei M., Shoda J., Thono E., Tsuboi K., Tokuuye K. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2009;74:831–836. doi: 10.1016/j.ijrobp.2008.10.073. [DOI] [PubMed] [Google Scholar]
  • 9.Hong T.S., Wo J.Y., Yeap B.Y., Ben-Josef E., McDonnell E.I., Blaszkowsky L.S., Kwak E.L., Allen J.N., Clark J.W., Goyal L., et al. Multi-institutional phase ii study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J. Clin. Oncol. 2016;34:460–468. doi: 10.1200/JCO.2015.64.2710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Kawashima M., Furuse J., Nishio T., Konishi M., Ishii H., Kinoshita T., Nagase M., Nihei K., Ogino T. Phase ii study of radiotherapy employing proton beam for hepatocellular carcinoma. J. Clin. Oncol. 2005;23:1839–1846. doi: 10.1200/JCO.2005.00.620. [DOI] [PubMed] [Google Scholar]
  • 11.Kim D.Y., Park J.W., Kim T.H., Kim B.H., Moon S.H., Kim S.S., Woo S.M., Koh Y.H., Lee W.J., Kim C.M. Risk-adapted simultaneous integrated boost-proton beam therapy (sib-pbt) for advanced hepatocellular carcinoma with tumour vascular thrombosis. Radiother. Oncol. 2017;122:122–129. doi: 10.1016/j.radonc.2016.12.014. [DOI] [PubMed] [Google Scholar]
  • 12.Kim T.H., Kim D.Y., Park J.W., Kim Y.I., Kim S.H., Park H.S., Lee W.J., Park S.J., Hong E.K., Kim C.M. Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable. Am. J. Clin. Oncol. 2006;29:568–575. doi: 10.1097/01.coc.0000239147.60196.11. [DOI] [PubMed] [Google Scholar]
  • 13.Kim T.H., Park J.W., Kim B.H., Kim D.Y., Moon S.H., Kim S.S., Lee J.H., Woo S.M., Koh Y.H., Lee W.J., et al. Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma. Oncotarget. 2018;9:4034–4043. doi: 10.18632/oncotarget.23428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Kim T.H., Park J.W., Kim Y.J., Kim B.H., Woo S.M., Moon S.H., Kim S.S., Koh Y.H., Lee W.J., Park S.J., et al. Phase i dose-escalation study of proton beam therapy for inoperable hepatocellular carcinoma. Cancer Res. Treat. 2015;47:34–45. doi: 10.4143/crt.2013.218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Kim T.H., Park J.W., Kim Y.J., Kim B.H., Woo S.M., Moon S.H., Kim S.S., Lee W.J., Kim D.Y., Kim C.M. Simultaneous integrated boost-intensity modulated radiation therapy for inoperable hepatocellular carcinoma. Strahlenther. Onkol. 2014;190:882–890. doi: 10.1007/s00066-014-0643-z. [DOI] [PubMed] [Google Scholar]
  • 16.Klein J., Dawson L.A. Hepatocellular carcinoma radiation therapy: Review of evidence and future opportunities. Int. J. Radiat. Oncol. Biol. Phys. 2013;87:22–32. doi: 10.1016/j.ijrobp.2012.08.043. [DOI] [PubMed] [Google Scholar]
  • 17.Lee S.U., Park J.W., Kim T.H., Kim Y.J., Woo S.M., Koh Y.H., Lee W.J., Park S.J., Kim D.Y., Kim C.M. Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Strahlenther. Onkol. 2014;190:806–814. doi: 10.1007/s00066-014-0604-6. [DOI] [PubMed] [Google Scholar]
  • 18.Rim C.H., Seong J. Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines. Radiat. Oncol. J. 2016;34:160–167. doi: 10.3857/roj.2016.01970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Dionisi F., Widesott L., Lorentini S., Amichetti M. Is there a role for proton therapy in the treatment of hepatocellular carcinoma? A systematic review. Radiother. Oncol. 2014;111:1–10. doi: 10.1016/j.radonc.2014.02.001. [DOI] [PubMed] [Google Scholar]
  • 20.Mizuhata M., Takamatsu S., Shibata S., Bou S., Sato Y., Kawamura M., Asahi S., Tameshige Y., Maeda Y., Sasaki M., et al. Respiratory-gated proton beam therapy for hepatocellular carcinoma adjacent to the gastrointestinal tract without fiducial markers. Cancers. 2018;10:58. doi: 10.3390/cancers10020058. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Shibata S., Takamatsu S., Yamamoto K., Mizuhata M., Bou S., Sato Y., Kawamura M., Asahi S., Tameshige Y., Maeda Y., et al. Proton beam therapy without fiducial markers using four-dimensional ct planning for large hepatocellular carcinomas. Cancers. 2018;10:71. doi: 10.3390/cancers10030071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Nakayama H., Sugahara S., Fukuda K., Abei M., Shoda J., Sakurai H., Tsuboi K., Matsuzaki Y., Tokuuye K. Proton beam therapy for hepatocellular carcinoma located adjacent to the alimentary tract. Int. J. Radiat. Oncol. Biol. Phys. 2011;80:992–995. doi: 10.1016/j.ijrobp.2010.03.015. [DOI] [PubMed] [Google Scholar]
  • 23.Kim J.Y., Lim Y.K., Kim T.H., Cho K.H., Choi S.H., Jeong H., Kim D.W., Park J.H., Shin D.H., Lee S.B., et al. Normal liver sparing by proton beam therapy for hepatocellular carcinoma: Comparison with helical intensity modulated radiotherapy and volumetric modulated arc therapy. Acta Oncol. 2015;54:1827–1832. doi: 10.3109/0284186X.2015.1009637. [DOI] [PubMed] [Google Scholar]
  • 24.Qi W.X., Fu S., Zhang Q., Guo X.M. Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: A systematic review and meta-analysis. Radiother. Oncol. 2015;114:289–295. doi: 10.1016/j.radonc.2014.11.033. [DOI] [PubMed] [Google Scholar]
  • 25.Llovet J.M., Bru C., Bruix J. Prognosis of hepatocellular carcinoma: The bclc staging classification. Semin. Liver Dis. 1999;19:329–338. doi: 10.1055/s-2007-1007122. [DOI] [PubMed] [Google Scholar]
  • 26.Bruix J., Llovet J.M. Major achievements in hepatocellular carcinoma. Lancet. 2009;373:614–616. doi: 10.1016/S0140-6736(09)60381-0. [DOI] [PubMed] [Google Scholar]
  • 27.Kwak H.W., Park J.W., Nam B.H., Yu A., Woo S.M., Kim T.H., Kim S.H., Koh Y.H., Kim H.B., Park S.J., et al. Clinical outcomes of a cohort series of patients with hepatocellular carcinoma in a hepatitis b virus-endemic area. J. Gastroenterol. Hepatol. 2014;29:820–829. doi: 10.1111/jgh.12470. [DOI] [PubMed] [Google Scholar]
  • 28.Lencioni R., de Baere T., Soulen M.C., Rilling W.S., Geschwind J.F. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology. 2016;64:106–116. doi: 10.1002/hep.28453. [DOI] [PubMed] [Google Scholar]
  • 29.Lencioni R., Kudo M., Ye S.L., Bronowicki J.P., Chen X.P., Dagher L., Furuse J., Geschwind J.F., de Guevara L.L., Papandreou C., et al. Gideon (global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib): Second interim analysis. Int. J. Clin. Pract. 2014;68:609–617. doi: 10.1111/ijcp.12352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Ueno S., Tanabe G., Nuruki K., Hamanoue M., Komorizono Y., Oketani M., Hokotate H., Inoue H., Baba Y., Imamura Y., et al. Prognostic performance of the new classification of primary liver cancer of japan (4th edition) for patients with hepatocellular carcinoma: A validation analysis. Hepatol. Res. 2002;24:395–403. doi: 10.1016/S1386-6346(02)00144-4. [DOI] [PubMed] [Google Scholar]
  • 31.Takeda A., Oku Y., Sanuki N., Kunieda E., Koike N., Aoki Y., Ohashi T., Iwabuchi S., Takatsuka K., Takeda T., et al. Dose volume histogram analysis of focal liver reaction in follow-up multiphasic ct following stereotactic body radiotherapy for small hepatocellular carcinoma. Radiother. Oncol. 2012;104:374–378. doi: 10.1016/j.radonc.2011.12.008. [DOI] [PubMed] [Google Scholar]
  • 32.Joiner M.C., Bentzen S.M. Basic Clinical Radiobiology. 3rd ed. Oxford University Press; New York, NY, USA: 2003. Time-dose relationships: The linear-quadrantic approach; pp. 121–133. [Google Scholar]
  • 33.Kim T.H., Kim D.Y., Park J.W., Kim S.H., Choi J.I., Kim H.B., Lee W.J., Park S.J., Hong E.K., Kim C.M. Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2007;67:225–231. doi: 10.1016/j.ijrobp.2006.08.015. [DOI] [PubMed] [Google Scholar]
  • 34.Lencioni R., Llovet J.M. Modified recist (mrecist) assessment for hepatocellular carcinoma. Semin. Liver Dis. 2010;30:52–60. doi: 10.1055/s-0030-1247132. [DOI] [PubMed] [Google Scholar]

Articles from Cancers are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES